Improved glycemic control can be better maintained with insulin lispro than with human regular insulin

Diabetes, Nutrition and Metabolism - Clinical and Experimental

Volumn 11, Issue 3, 1998, Pages 194-199

  Jansson, P A ^a   Ebeling, P ^b   Smith, U ^a   Conget, I ^c   Coves, M J ^c   Gomis, R ^c   Lalli, C ^d   Del Sindaco, P ^d   Bolli, G B ^d   Koivisto, V A ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Glycemic control; Insulin lispro; Insulin therapy; Type 1 diabetes

Indexed keywords

HUMAN INSULIN; INSULIN LISPRO;

ADULT; ARTICLE; BODY WEIGHT; DIABETES CONTROL; DIABETES MELLITUS; DRUG DOSE; FEMALE; FINLAND; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; ITALY; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; PRIORITY JOURNAL; SATISFACTION; SPAIN; SWEDEN; THERAPY;

EID: 7844249244     PISSN: 03943402     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Pirart J.: Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed between 1947-1973. Diabetes Care 1: 168-188, 1978.
2. Hansen K.F., Dahl-Jörgensen K., Lauritzen T., Feldt-Rasmussen B., Brichmann-Hanssen O., Deckert T.: Diabetic control and microvascular complications: the nearnormoglycemic experience. Diabetologia 29: 677-685, 1986.
3. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329: 977-986, 1993.
4. Reichard P., Nilsson B.-Y., Rosenqvist U.: The effect ot long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N. Engl. J. Med. 329: 304-309, 1993.
5. Garg S.K., Carmain J.A., Braddy K.C., Anderson J.H., Vignati L., Jennings M.K. Chase H.P.: Pre-meal insulin analogue insulin lispro vs Humulin® insulin treatment in young subjects with type 1 diabetes. Diabetic Med. 13: 47-52, 1996.
6. Anderson J.H., Brunelle R.L., Koivisto V.A., Ptützner A., Trautmann M.E., Vignati L. Jr., DiMarchi R.: Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin analogue treatment. Multicenter Insulin Lispro Study Group. Diabetes 46: 265-270, 1997.
7. Anderson J.H., Brunelle R.L., Keohane P., Koivisto V.A., Trautmann M.E., Vignati L., Di Marchi R.: Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch. Intern. Med. 157: 1249-1255, 1997.
8. Pfützner A., Küstner E., Forst T., Schulze-Schleppinghoff B., Trautmann M., Haslbeck M. Schatz H., Beyes J. on behalf of the German Insulin Lispro/IDDM study group: Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Exp. Clin. Endocrinol. 104: 25-30, 1996.
9. Brunelle R., Llewelyn J., Vignati L., Anderson J., Koivisto V.A.: Humalog reduces the incidence of severe hypoglycemia in IDDM patients. Diabetologia 40 (Suppl. 1): A352, 1997.
10. Torlone E., Pampanelli S., Lalli C., Del Sindaco P., Di Vicenzo A., Rambotti A.M., Modarelli F., Epifano L., Kassi G., Perriello G., Brunetti P., Bolli G.: Effects of the short-acting insulin analog [Lys (B28), Pro [B29)] on postprandial blood glucose control in IDDM. Diabetes Care 19: 945-952, 1996.
11. Holleman F., Hoekstra J.B.L.: Insulin lispro. N. Engl. J. Med. 337: 176-183, 1997.
12. Zinman B., Tildesley H., Chiasson J.-L., Tsui E., Strack T.: Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 46: 440-443, 1997.
13. lc without increasing hypoglycemia risk in diabetic patients treated with insulin lispro in external pumps. Diabetologia 40 (Suppl. 1): A10, 1997.
14. Pfützner A., Renner R., the German Humalog CSII Study Group: CSII therapy with insulin pumps using insulin lispro. Diabetes 46 (Suppl. 1): 34, 1996.
15. Ebeling P., Jansson P.-A., Smith U., Lalli C., Bolli G.B., Koivisto V.A.: Strategies towards improved control during insulin lispro therapy in IDDM: importance of basal insulin. Diabetes Care 20: 1287-1289, 1997.
16. WHO Expert Committee on Diabetes Mellitus: Second Report: World Health Organization, Technical Report Series: 646. Geneva, WHO, 1980.
17. Conget I., Cover M.J., Costa M.A., Gomis R.: Ajuste de la dosis de insulina durante el tratamiento con insulina lispro en pacientes con diabetes mellitus tipo I. Endocrinologia 44: 288-290, 1997.
18. lc by high performance cation exchange chromatography. Clin. Chem. 26: 3-7, 1980.
19. Bradley C.: Diabetes treatment satisfaction questionnaire (DTSQ). In: Bradley C. (Ed.), Handbook of psychology and diabetes. Harwood Academic Publishers GmbH, 1994, p.111-132.
20. Howey D.C., Bowsher R.R., Brunelle R., Woodworth J.R.: (Lys (B28), Pro (B29))- human insulin. A rapidly absorbed analogue of human insulin. Diabetes 43: 396-402, 1994.
21. Diabetes Control and Complications Trial Research Group: The absence of glycemic threshold for the development of long-term: the perspective of Diabetes Control and Complications Trial. Diabetes 45: 1289-1298, 1996.
22. Kotsanos J.G., Vignati L., Huster W., Andrejasich C., Boggs M.B., Jacobson A.M., Marrero D., Mathias S.D., Patrick D., Zalami S., Andersson J.: Health-related quality-of-life results from multinational clinical trials of insulin lispro. Diabetes Care 20: 948-958, 1997.